{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:06:09Z","timestamp":1771459569595,"version":"3.50.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Human epidermal growth factor receptor 2 (HER2) status in endometrial cancer is usually determined by immunohistochemistry and\/or in situ hybridization. We employed a novel HER2 gene protein assay (GPA) to simultaneously assesses HER2 gene amplification and protein expression in high-grade endometrial cancers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed GPA in 180 endometrial cancers, including 106 serous carcinomas, 34 carcinosarcomas, and 40 mixed epithelial carcinomas. HER2 status was determined using the 2018 HER2 guidelines for breast carcinoma, and HER2 intratumoral heterogeneity (ITH) was examined. Clinicopathologic characteristics were collected and correlated with HER2 status.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>HER2 positivity was noted in 32% of serous carcinomas, significantly higher than in carcinosarcomas (5.9%) and mixed carcinomas (12.5%). HER2 ITH was detected in 32% of serous carcinomas, significantly greater than in carcinosarcomas (8.8%) and mixed carcinomas (10%). Patients with carcinosarcoma had a significantly lower overall survival than patients with serous or mixed epithelial carcinoma, but HER2 status caused no difference in survival in patients with serous carcinoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>HER2 GPA can be used to accurately determine HER2 status in endometrial cancers and is a highly valuable tool for identifying HER2 heterogeneity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqac179","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T20:55:45Z","timestamp":1677704145000},"page":"464-473","source":"Crossref","is-referenced-by-count":4,"title":["HER2 Gene Protein Assay: A Robust Tool for Evaluating HER2 Status and Intratumoral Heterogeneity in Endometrial Cancers"],"prefix":"10.1093","volume":"159","author":[{"given":"Saba","family":"Shafi","sequence":"first","affiliation":[{"name":"Department of Pathology, The Ohio State University Wexner Medical Center , Columbus, OH , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Nitta","sequence":"additional","affiliation":[{"name":"Roche Ventana Medical Systems , Tucson, AZ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manan","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, The Ohio State University Wexner Medical Center , Columbus, OH , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bindu","family":"Challa","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University Wexner Medical Center , Columbus, OH , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil V","family":"Parwani","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University Wexner Medical Center , Columbus, OH , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1325-1696","authenticated-orcid":false,"given":"Zaibo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University Wexner Medical Center , Columbus, OH , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"2023050207545776600_CIT0001","first-page":"185","article-title":"Immunoexpression and clinical significance of the PTEN and MLH1 proteins in endometrial carcinomas","volume":"61","author":"B\u0105kiewicz","year":"2011","journal-title":"Pol J Pathol."},{"key":"2023050207545776600_CIT0002","first-page":"307","article-title":"HER-2\/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas","volume":"32","author":"Engelsen","year":"2008","journal-title":"Int J Oncol."},{"key":"2023050207545776600_CIT0003","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3322\/caac.21153","article-title":"Cancer statistics for Hispanics\/Latinos, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin."},{"key":"2023050207545776600_CIT0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2007.09.007","article-title":"An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"108","author":"Grushko","year":"2008","journal-title":"Gynecol Oncol."},{"key":"2023050207545776600_CIT0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science."},{"key":"2023050207545776600_CIT0006","first-page":"4087","article-title":"Overexpression of HER-2\/neu is associated with poor survival in advanced epithelial ovarian cancer","volume":"50","author":"Berchuck","year":"1990","journal-title":"Cancer Res."},{"key":"2023050207545776600_CIT0007","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/modpathol.2011.47","article-title":"HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma","volume":"24","author":"Hu","year":"2011","journal-title":"Mod Pathol."},{"key":"2023050207545776600_CIT0008","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/PAI.0b013e31821c821c","article-title":"HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment","volume":"20","author":"Kunz","year":"2012","journal-title":"Appl Immunohistochem Mol Morphol."},{"key":"2023050207545776600_CIT0009","article-title":"Basic science of HER-2\/neu: a review","author":"Hung"},{"key":"2023050207545776600_CIT0010","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/cncr.21308","article-title":"Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma","volume":"104","author":"Santin","year":"2005","journal-title":"Cancer."},{"key":"2023050207545776600_CIT0011","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/PGP.0000000000000690","article-title":"Does specimen type have an impact on HER2 status in endometrial serous carcinoma?","volume":"40","author":"Rottmann","year":"2021","journal-title":"Int J Gynecol Pathol."},{"key":"2023050207545776600_CIT0012","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1309\/AJCPKIVVW4OBPX6I","article-title":"Dual HER2 gene protein assay: focused study of breast cancers with 2+ immunohistochemical expression","volume":"143","author":"Li","year":"2015","journal-title":"Am J Clin Pathol."},{"key":"2023050207545776600_CIT0013","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/PAS.0000000000001682","article-title":"HER-2 amplification in uterine serous carcinoma and serous endometrial intraepithelial carcinoma","volume":"45","author":"Banet","year":"2021","journal-title":"Am J Surg Pathol."},{"key":"2023050207545776600_CIT0014","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/gcc.22113","article-title":"Marked heterogeneity of HER2\/NEU gene amplification in endometrial serous carcinoma","volume":"52","author":"Buza","year":"2013","journal-title":"Genes Chromosomes Cancer."},{"key":"2023050207545776600_CIT0015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-017-4453-8","article-title":"HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma","volume":"166","author":"Hou","year":"2017","journal-title":"Breast Cancer Res Treat."},{"key":"2023050207545776600_CIT0016","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.mpdhp.2019.10.014","article-title":"The assessment of HER2 status and its clinical implication in breast cancer","volume":"26","author":"Hou","year":"2020","journal-title":"Diagn Histopathol."},{"key":"2023050207545776600_CIT0017","first-page":"1271","article-title":"Overexpression of HER-2\/neu in uterine serous papillary cancer","volume":"8","author":"Santin","year":"2002","journal-title":"Clin Cancer Res."},{"key":"2023050207545776600_CIT0018","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5858\/arpa.2012-0416-RA","article-title":"HER2\/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges","volume":"138","author":"Buza","year":"2014","journal-title":"Arch Pathol Lab Med."},{"key":"2023050207545776600_CIT0019","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol."},{"key":"2023050207545776600_CIT0020","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol."},{"key":"2023050207545776600_CIT0021","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1158\/1078-0432.CCR-0428-03","article-title":"Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization","volume":"10","author":"Isola","year":"2004","journal-title":"Clin Cancer Res."},{"key":"2023050207545776600_CIT0022","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/PDM.0b013e31817f5227","article-title":"The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer","volume":"18","author":"Pedersen","year":"2009","journal-title":"Diagn Mol Pathol."},{"key":"2023050207545776600_CIT0023","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1440-1827.2010.02553.x","article-title":"Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH)","volume":"60","author":"Kato","year":"2010","journal-title":"Pathol Int."},{"key":"2023050207545776600_CIT0024","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/PAS.0b013e3181d96231","article-title":"Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility","volume":"34","author":"Papouchado","year":"2010","journal-title":"Am J Surg Pathol."},{"key":"2023050207545776600_CIT0025","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/modpathol.2011.9","article-title":"Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer","volume":"24","author":"Koh","year":"2011","journal-title":"Mod Pathol."},{"key":"2023050207545776600_CIT0026","doi-asserted-by":"crossref","first-page":"276","DOI":"10.4048\/jbc.2011.14.4.276","article-title":"Silver-enhanced in situ hybridization as an alternative to fluorescence in situ hybridization for assaying HER2 amplification in clinical breast cancer","volume":"14","author":"Park","year":"2011","journal-title":"J Breast Cancer."},{"key":"2023050207545776600_CIT0027","first-page":"89","article-title":"HER2 gene protein assay is useful to determine HER2 status and evaluate HER2 heterogeneity in HER2 equivocal breast cancer","volume":"147","author":"Hou","year":"2017","journal-title":"Am J Clin Pathol."},{"key":"2023050207545776600_CIT0028","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol."},{"key":"2023050207545776600_CIT0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","article-title":"Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study","volume":"159","author":"Erickson","year":"2020","journal-title":"Gynecol Oncol."},{"key":"2023050207545776600_CIT0030","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/PAS.0000000000001870","article-title":"HER2 overexpression and amplification in uterine carcinosarcomas with serous morphology","volume":"46","author":"Jenkins","year":"2022","journal-title":"Am J Surg Pathol."},{"key":"2023050207545776600_CIT0031","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13058-022-01519-x","article-title":"Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society","volume":"24","author":"Won","year":"2022","journal-title":"Breast Cancer Res."},{"key":"2023050207545776600_CIT0032","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/159\/5\/464\/50149932\/aqac179.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/159\/5\/464\/50149932\/aqac179.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T07:55:41Z","timestamp":1683014141000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/159\/5\/464\/7066965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3,1]]},"published-print":{"date-parts":[[2023,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqac179","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,3,1]]}}}